contrafect - Robuta Search

https://www.globenewswire.com/fr/news-release/2023/09/19/2745601/0/en/ContraFect-to-Present-at-the-ASM-ESCMID-Joint-Conference-on-Drug-Development.html ContraFect to Present at the ASM/ESCMID Joint Conference on YONKERS, New York, Sept. 19, 2023 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq: CFRX), a clinical-stage biotechnology company focused on the... at the present asm escmid joint https://www.globenewswire.com/de/news-release/2023/04/03/2639585/0/en/ContraFect-Announces-Initiation-of-a-Phase-1b-2-Study-of-Exebacase-in-Patients-with-Chronic-Prosthetic-Joint-Infections-of-the-Knee.html ContraFect Announces Initiation of a Phase 1b/2 Study of YONKERS, New York, April 03, 2023 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq: CFRX), a clinical-stage biotechnology company focused on the... of a announces initiation phase study https://www.globenewswire.com/fr/news-release/2022/01/06/2362815/0/en/contrafect-announces-award-from-the-cystic-fibrosis-foundation-to-evaluate-exebacase-as-a-potential-treatment-for-serious-mrsa-lung-infections-associated-with-cystic-fibrosis.html ContraFect Announces Award from the Cystic Fibrosis YONKERS, N.Y., Jan. 06, 2022 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq: CFRX), a late clinical-stage biotechnology company focused on the... from the announces award cystic fibrosis https://www.globenewswire.com/fr/news-release/2023/06/27/2695308/0/en/ContraFect-Enters-Into-a-Warrant-Exercise-Transaction-for-Proceeds-of-9-6-Million.html ContraFect Enters Into a Warrant Exercise Transaction for YONKERS, N.Y., June 27, 2023 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq: CFRX), a clinical-stage biotechnology company focused on the discovery... enters warrant exercise transaction https://www.globenewswire.com/de/news-release/2023/04/20/2650996/0/en/ContraFect-Data-Presentations-at-the-33rd-Annual-ECCMID-Meeting-Highlight-the-Potential-Efficacy-of-Lysin-CF-370-Against-Antibiotic-Resistant-Gram-negative-Pathogens.html ContraFect Data Presentations at the 33rd Annual ECCMID YONKERS, N.Y., April 20, 2023 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq: CFRX), a clinical-stage biotechnology company focused on the discovery... data presentations annual https://www.globenewswire.com/fr/news-release/2022/05/20/2447674/0/en/contrafect-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4.html ContraFect Announces Inducement Grants Under Nasdaq Listing YONKERS, N.Y., May 20, 2022 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq: CFRX) (ContraFect), a late clinical-stage biotechnology company focused... announces inducement grants nasdaq listing https://rss.globenewswire.com/news-release/2023/08/28/2732525/0/en/ContraFect-to-Present-at-the-World-Anti-Microbial-Resistance-Congress-2023.html ContraFect to Present at the World Anti-Microbial YONKERS, N.Y., Aug. 28, 2023 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq: CFRX), a clinical-stage biotechnology company focused on the discovery... at the present world anti microbial https://www.globenewswire.com/de/news-release/2022/12/19/2576681/0/en/ContraFect-Provides-Update-from-the-Futility-Analysis-of-the-Phase-3-DISRUPT-Study-of-Exebacase.html ContraFect Provides Update from the Futility Analysis of Take the Deep Dive in a Virtual Fireside Chat to be Held in Q1 2023... from the provides update futility analysis https://www.globenewswire.com/de/news-release/2023/03/31/2638628/0/en/ContraFect-Reports-Fourth-Quarter-2022-and-Full-Year-2022-Financial-Results-and-Provides-Business-Update.html ContraFect Reports Fourth Quarter 2022 and Full Year 2022 YONKERS, N.Y., March 31, 2023 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq: CFRX), a clinical-stage biotechnology company focused on the discovery... fourth quarter reports full year https://www.globenewswire.com/de/news-release/2023/04/26/2655181/0/en/ContraFect-Announces-First-Patient-Dosed-in-the-Phase-1b-2-Study-of-Exebacase-in-Patients-with-Chronic-Prosthetic-Joint-Infections-of-the-Knee.html ContraFect Announces First Patient Dosed in the Phase 1b/2 YONKERS, N.Y., April 26, 2023 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq: CFRX), a clinical-stage biotechnology company focused on the discovery... first patient in the announces dosed phase